LOS ANGELES—Salt AI, a leader in contextual AI for enterprise applications in life sciences and health tech, has announced the addition of four seasoned executives to its leadership team. The appointments follow the company’s recent $10 million funding round and mark a strategic expansion as Salt AI accelerates its growth and scales its adaptive SaaS platform across the life sciences sector. The new leaders bring deep expertise in biotechnology, artificial intelligence, and commercialization, strengthening Salt AI’s ability to deliver tailored AI solutions that address complex challenges in drug discovery, clinical research, and healthcare operations. Their collective experience spans global pharmaceutical companies, AI startups, and venture-backed technology firms, positioning the company to drive innovation at the intersection of data, science, and enterprise software. The leadership additions come at a pivotal moment as demand for intelligent, context-aware AI tools in life sciences continues to rise. Salt AI’s platform enables organizations to extract actionable insights from unstructured scientific data—such as research papers, clinical trial reports, and regulatory documents—using advanced natural language processing and domain-specific training. With this infusion of talent and capital, Salt AI is expanding its engineering, product, and go-to-market teams to support broader adoption across pharmaceutical companies, biotech startups, and academic institutions. The company is also enhancing its AI models to better understand nuanced scientific terminology and evolving research landscapes. The recent funding round reflects strong investor confidence in Salt AI’s mission to transform how life sciences organizations leverage data. The company is now focused on deepening partnerships, accelerating product development, and scaling its platform to meet the growing needs of a data-driven research environment.